These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 8213718)
41. The use of laser-nephelometry in evaluating fibrinogenaemia in patients with hepatocarcinoma and cirrhosis. Girolami A; Antico S; Pengo V; Ruffato G; Callegari F; Cappellato M Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):920-7. PubMed ID: 2419222 [TBL] [Abstract][Full Text] [Related]
42. [Rheumatoid factor in liver cirrhosis and hepatoma (author's transl)]. Caballero Vallés PJ; Miramón García MA; Roldán Rincón AC; Ruiz Pérez de Villar MJ Med Clin (Barc); 1982 Feb; 78(3):84-7. PubMed ID: 6281590 [No Abstract] [Full Text] [Related]
43. Circadian rhythmicity of growth hormone at high altitude in man. Sawhney RC; Malhotra AS Indian J Physiol Pharmacol; 1991 Jan; 35(1):55-7. PubMed ID: 1917013 [TBL] [Abstract][Full Text] [Related]
44. Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Fernández-Rodriguez CM; Prada I; Andrade A; Moreiras M; Guitián R; Aller R; Lledó JL; Cacho G; Quiroga J; Prieto J Dig Dis Sci; 2001 Jun; 46(6):1313-20. PubMed ID: 11414310 [TBL] [Abstract][Full Text] [Related]
46. Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients. Parisse S; Ferri F; Persichetti M; Mischitelli M; Abbatecola A; Di Martino M; Lai Q; Carnevale S; Lucatelli P; Bezzi M; Rossi M; De Santis A; Spagnoli A; Ginanni Corradini S Sci Rep; 2021 Jul; 11(1):15184. PubMed ID: 34312420 [TBL] [Abstract][Full Text] [Related]
47. [Clinical studies on the relation of abnormal growth hormone secretions to hepatic diabetes mellitus in patients with hepatocellular carcinoma]. Kamijo K; Kawasaki K; Sato M; Yachi A Gan No Rinsho; 1989 Jun; 35(7):775-9. PubMed ID: 2544747 [TBL] [Abstract][Full Text] [Related]
48. Some haematological observations of Kenyan hepatocellular carcinoma (HCC) patients. Mukiibi JM; Mwaungulu GS; Wankya BM East Afr Med J; 1982 Feb; 59(2):118-26. PubMed ID: 6290180 [No Abstract] [Full Text] [Related]
49. [Prolactin and growth hormone in cirrhotic patients with and without physical signs of feminization]. Martínez Verano JA; Alvarez Burgos ML; Borque Ibarra M; Casanueva F Rev Clin Esp; 1982 Apr; 165(1):23-6. PubMed ID: 6812174 [No Abstract] [Full Text] [Related]
50. Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma. Sawamura T; Nakada H; Hazama H; Shiozaki Y; Sameshima Y; Tashiro Y Gastroenterology; 1984 Dec; 87(6):1217-21. PubMed ID: 6092193 [TBL] [Abstract][Full Text] [Related]
51. Somatomedin C (IGF I) plasma levels after orthotopic liver transplantation (OLT) in end-stage cirrhotic patients. Corti A; De Gasperi A; Oppizzi G; Pannacciulli E; Cristalli A; Fantini G; Mazza E; Prosperi M; Rocchini A; Sabbadini D; Savi C; Scaiola A; Vai S; Romani F; DeCarlis L; Rondinara GF Transpl Int; 1992; 5 Suppl 1():S185-6. PubMed ID: 14621770 [TBL] [Abstract][Full Text] [Related]
52. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Saito K; Inoue S; Saito T; Kiso S; Ito N; Tamura S; Watanabe H; Takeda H; Misawa H; Togashi H; Matsuzawa Y; Kawata S Gut; 2002 Jul; 51(1):100-4. PubMed ID: 12077100 [TBL] [Abstract][Full Text] [Related]
53. Primary hepatocellular carcinoma with severe hypoglycemia: involvement of insulin-like growth factors. Yonei Y; Tanaka M; Ozawa Y; Miyazaki K; Tsukada N; Inada S; Inagaki Y; Miyamoto K; Suzuki O; Okawa H Liver; 1992 Apr; 12(2):90-3. PubMed ID: 1320177 [TBL] [Abstract][Full Text] [Related]
54. Effect of metoclopramide on serum growth hormone levels in cirrhotic men. Volpi R; Coiro V; Salvi M; Pelosi G; Mancini P; Chiodera P J Endocrinol Invest; 1983 Apr; 6(2):101-5. PubMed ID: 6863846 [TBL] [Abstract][Full Text] [Related]
55. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. Scharf JG; Schmitz F; Frystyk J; Skjaerbaek C; Moesus H; Blum WF; Ramadori G; Hartmann H J Hepatol; 1996 Nov; 25(5):689-99. PubMed ID: 8938547 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of the synthetic somatostatin analogue SMS 201-995 in patients with hypoglycaemia associated with hepatocellular carcinoma. Joffe BI; Kew MC; Panz VR; Kalk WJ; Shires R; Wing J; Seftel HC Br J Cancer; 1988 Jul; 58(1):91-2. PubMed ID: 2844221 [No Abstract] [Full Text] [Related]
57. Hyperthyroxinaemia in hepatocellular carcinoma: relation to thyroid binding globulin in the clinical and preclinical stages of the disease. Alexopoulos A; Hutchinson W; Bari A; Keating JJ; Johnson PJ; Williams R Br J Cancer; 1988 Mar; 57(3):313-6. PubMed ID: 2833301 [TBL] [Abstract][Full Text] [Related]
58. Serum insulin-like growth factor II in chronic liver disease. Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y; Kato K; Katada N; Sugimoto Y; Takeichi M Dig Dis Sci; 1989 Mar; 34(3):338-42. PubMed ID: 2537715 [TBL] [Abstract][Full Text] [Related]
59. Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. Caufriez A; Reding P; Urbain D; Golstein J; Copinschi G J Endocrinol Invest; 1991 Apr; 14(4):317-21. PubMed ID: 1865082 [TBL] [Abstract][Full Text] [Related]